← back to search

Brent D. G. Page

University of British Columbia · CA
Area of research
Materials Chemistry · Oncology
Research interest
Research interests include Cytokine Signaling Pathways and Interactions, Crystallization and Solubility Studies, X-ray Diffraction in Crystallography, and Cancer Mechanisms and Therapy.
h-index
26
citations
2,598
works
112
NIH funding
primary concept
email

Recent publications

Disrupting TSLP–TSLP receptor interactions via putative small molecule inhibitors yields a novel and efficient treatment option for atopic diseases
EMBO Molecular Medicine 2024cited by 17position: middledoi
The antimicrobial drug pyrimethamine inhibits STAT3 transcriptional activity by targeting the enzyme dihydrofolate reductase
Journal of Biological Chemistry 2021cited by 50position: middledoi
NUDT15-mediated hydrolysis limits the efficacy of anti-HCMV drug ganciclovir
Cell chemical biology 2021cited by 23position: middledoi
Oncogenic Kinase Cascades Induce Molecular Mechanisms That Protect Leukemic Cell Models from Lethal Effects of De Novo dNTP Synthesis Inhibition
Cancers 2021cited by 10position: middledoi
Irreversible TrxR1 inhibitors block STAT3 activity and induce cancer cell death
Science Advances 2020cited by 72position: lastdoi
Targeted NUDT5 inhibitors block hormone signaling in breast cancer cells
Nature Communications 2018cited by 122position: firstdoi
Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies
Nature Medicine 2017cited by 141position: middledoi
Crystal structure, biochemical and cellular activities demonstrate separate functions of MTH1 and MTH2
Nature Communications 2015cited by 114position: middledoi
Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia
Leukemia 2014cited by 133position: middledoi
Design, Optimization, and Pre-Clinical Evaluation of Direct, Mechanism-Based STAT3 Inhibitors for Treating Myeloid Disorders
Blood 2014cited by 0position: middledoi
STAT3 activity is necessary and sufficient for the development of immune‐mediated myocarditis in mice and promotes progression to dilated cardiomyopathy
EMBO Molecular Medicine 2013cited by 51position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Ann‐Sofie Jemth · Science for Life Laboratory3 papers (2015–2021)Thomas Helleday · Science for Life Laboratory3 papers (2015–2021)Pål Stenmark · Lund University3 papers (2015–2021)Patrick T. Gunning · Queen's University3 papers (2013–2021)Nicholas C.K. Valerie · Karolinska University Hospital3 papers (2015–2021)Sanaz Attarha · Karolinska Institutet2 papers (2020–2021)Megan Carter · University of Kentucky2 papers (2015–2018)Evert Homan · Science for Life Laboratory2 papers (2018–2021)Sean G. Rudd · Science for Life Laboratory2 papers (2018–2021)Ulrika Warpman Berglund · Orexo (Sweden)2 papers (2015–2021)Matthieu Desroses · Sprint Bioscience (Sweden)2 papers (2015–2021)Martin Scobie · Orexo (Sweden)2 papers (2018–2021)Ingrid Almlöf · Karolinska University Hospital2 papers (2018–2021)Martin Haraldsson · Science for Life Laboratory1 papers (2020–2020) · 1 papers (2013–2013)Peng Wang · Nanchang University1 papers (2021–2021)Malti Dumbani · Charité - Universitätsmedizin Berlin1 papers (2024–2024) · 1 papers (2013–2013)Kimberly R. Reynolds · University of Utah1 papers (2014–2014) · 1 papers (2013–2013)